Thomas A Lanz

Years Active: 2019-2021
Publications (10 Years): 3

Pfizer Global Research and Development

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Pfizer Global Research and Development

United States

Director :: Investigative Toxicology

Biogen

United States

Scientist II :: Translational Biology

Publications

Wei Chou Tseng, Veronica Reinhart, Thomas A Lanz, Mark L Weber, Jincheng Pang, Kevin Xuong Vinh Le, Robert D Bell, Patricio O'Donnell, Derek L Buhl
Schizophrenia-associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor and innate immune signaling. Translational psychiatry 11 (1) (2021)
Jonathan Garst-Orozco, Ruchi Malik, Thomas A Lanz, Mark L Weber, Hualin Xi, Dominique Arion, John F Enwright, David A Lewis, Patricio O'Donnell, Vikaas S Sohal, Derek L Buhl
GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneurons. PloS one 15 (6) (2020)
Zhicheng Shao, Haneul Noh, Woong Bin Kim, Peiyan Ni, Christine Nguyen, Sarah E Cote, Elizabeth Noyes, Joyce Zhao, Teagan Parsons, James M Park, Kelvin Zheng, Joshua J Park, Joseph T Coyle, Daniel R Weinberger, Richard E Straub, Karen F Berman, Jose Apud, Dost Ongur, Bruce M Cohen, Donna L McPhie, Judith L Rapoport, Roy H Perlis, Thomas A Lanz, Hualin Simon Xi, Changhong Yin, Weihua Huang, Teruyoshi Hirayama, Emi Fukuda, Takeshi Yagi, Sulagna Ghosh, Kevin C Eggan, Hae-Young Kim, Leonard M Eisenberg, Alexander A Moghadam, Patric K Stanton, Jun-Hyeong Cho, Sangmi Chung
Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. Nature neuroscience 22 (2) (2019)

Thomas A Lanz.css-eqlu8i{font-size:small;padding-left:4px;}